What is NERV's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.15B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NERV?

P/E (TTM) is n/a and 52-week range is $2.24 to $12.46 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NERV figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NERV?

The company profile lists net income (TTM) near $-1.33B, EPS (TTM) near $-28.45 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Minerva Neurosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 46.6M shares outstanding, ISIN US6033802058 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Minerva Neurosciences Inc

$NERV

Health Care · Biotechnology

IR Run Scenarios

$3.18

-1.24%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.

Employees

Website

www.minervaneurosciences.com/

IPO

2014-06-25

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)